Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$54.48

-2.51 (-4.40%)

, INSM

Insmed

$29.32

-0.78 (-2.59%)

04:55
11/30/17
11/30
04:55
11/30/17
04:55

Evercore ISI to hold a conference

BioPharma Catalyst / Deep Dive Conference is being held in Boston on November 29-30.

JUNO

Juno Therapeutics

$54.48

-2.51 (-4.40%)

INSM

Insmed

$29.32

-0.78 (-2.59%)

EXEL

Exelixis

$26.10

-0.91 (-3.37%)

BMY

Bristol-Myers

$62.90

0.38 (0.61%)

OVID

Ovid Therapeutics

$11.21

0.5 (4.67%)

BLUE

bluebird bio

$167.30

0.85 (0.51%)

DOVA

Dova Pharmaceuticals

$28.27

0.44 (1.58%)

LLY

Eli Lilly

$84.96

-0.09 (-0.11%)

DVAX

Dynavax

$19.50

-0.05 (-0.26%)

GWPH

GW Pharmaceuticals

$120.57

-3.5 (-2.82%)

BIIB

Biogen

$319.96

2.82 (0.89%)

AMGN

Amgen

$172.23

1.97 (1.16%)

CRSP

Crispr Therapeutics

$18.66

-0.55 (-2.86%)

ONCE

Spark Therapeutics

$73.27

0.34 (0.47%)

ALNY

Alnylam

$128.14

-1.6 (-1.23%)

DERM

Dermira

$24.05

0.71 (3.04%)

TOCA

Tocagen

$11.79

0.48 (4.24%)

JAZZ

Jazz Pharmaceuticals

$137.87

-1.74 (-1.25%)

RGNX

Regenxbio

$26.80

-1.45 (-5.13%)

  • 30

    Nov

  • 30

    Nov

  • 01

    Dec

  • 02

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

  • 14

    Dec

  • 12

    Jan

  • 18

    Jan

  • 03

    Feb

  • 15

    Feb

  • 05

    Mar

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 21

    May

  • 28

    May

  • 30

    Jun

JUNO Juno Therapeutics
$54.48

-2.51 (-4.40%)

11/03/17
RAJA
11/03/17
NO CHANGE
Target $61
RAJA
Outperform
Juno Therapeutics price target raised to $61 from $45 at Raymond James
Raymond James analyst Reni Benjamin raised Juno Therapeutics' price target to $61 from $45 and reiterated his Outperform rating following the Q3 report and update on all ongoing clinical programs. The analyst believes JCAR017 could potentially be a differentiated CAR T product and compete effectively with Yescarta and Kymriah. Further, with key readouts from multiple programs anticipated at upcoming medical conferences, the steady progress of the portfolio of products, including the BCMA CAR-T franchise as well as 5 products targeting solid tumors with data expected in 2018, and a strong cash position, Benjamin continues to recommend shares.
11/02/17
LEER
11/02/17
NO CHANGE
Target $56
LEER
Outperform
Juno Therapeutics price target raised to $56 from $34 at Leerink
Leerink analyst Michael Schmidt raised his price target for Juno Therapeutics to $56 from $34 after the company disclosed Q13 financial results and provided a pipeline update that was generally in-line with expectations. The analyst reiterates an Outperform rating on the shares.
11/02/17
RHCO
11/02/17
UPGRADE
Target $65
RHCO
Buy
Juno Therapeutics upgraded to Buy from Hold at SunTrust
SunTrust analyst Peter Lawson upgraded Juno Therapeutics to Buy from Hold and raised his price target to $65 from $25. Lawson notes that the company's JCAR017 demonstrated best-in-class safety and efficacy in Non-Hodgkin lymphoma, giving Juno a "clear advantage" relative to peers. The analyst adds that competitor data do not pose any immediate threats, positioning the company as a possible takeover target.
11/02/17
WEDB
11/02/17
NO CHANGE
Target $64
WEDB
Outperform
Juno Therapeutics price target raised to $64 from $42 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Juno Therapeutics to $64 from $42 to reflect new market adoption estimates for '017 in DLBCL. The analyst notes that the ASH update shows 6-month response rates with JCAR017 in TRANSCEND at high dose are superior to that achieved with competing CAR-Ts. With safety also appearing to be best-in-class, and potentially supportive of community based distribution in the outpatient setting, Nierengarten believes JCAR017 could establish a dominant position in marketplace despite later arrival. He reiterates an Outperform rating on the shares.
INSM Insmed
$29.32

-0.78 (-2.59%)

09/05/17
EVER
09/05/17
NO CHANGE
Target $40
EVER
Insmed price target raised to $40 from $28 at Evercore ISI
09/05/17
LEER
09/05/17
NO CHANGE
Target $36
LEER
Outperform
Insmed price target raised to $36 from $27 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Insmed shares to $36 citing this morning's "better-than-expected" top-line results from the company's Phase 3 study for Alis in nontuberculous mycobacterium lung disease. The stock in midday trading is up 106%, or $13.06, to $25.35. The analyst continues to project a U.S. market launch in 2019 and now estimates peak revenue of $1.6B by 2031. Label expansion opportunities and earlier regulatory approvals may present further upside, Schwartz tells investors in a research note. He reiterates an Outperform rating on Insmed.
09/06/17
BARD
09/06/17
NO CHANGE
Target $32
BARD
Outperform
Insmed price target raised to $32 from $23 at Baird
Baird analyst Brian Skorney raised his price target on Insmed to $32 from $23 following the results of its long-awaited Phase 3 CONVERT data. The analyst noted its primary endpoints were better than expected. The secondary endpoints were not as positive, but he does not believe that will affect its approvability. Skorney reiterated his Outperform rating on Insmed shares.
09/05/17
COWN
09/05/17
NO CHANGE
Target $54
COWN
Outperform
Insmed 'strong' efficacy, safety data will drive approvals, says Cowen
Cowen analyst Ritu Baral noted that Insmed reported "strong" efficacy and safety data for ALIS, which she thinks will drive approval of the drug in the U.S., EU and Japan. Given the increased probability of success, she set a $54 price target on Insmed shares, which have more than doubled to $26.37 in early afternoon trading.
EXEL Exelixis
$26.10

-0.91 (-3.37%)

09/22/17
RHCO
09/22/17
NO CHANGE
RHCO
Exelixis trial likely to be continued, says SunTrust
SunTrust analyst Peter Lawson says that the trial of Exelixis' cabozantinib.in liver cancer will most likely be continued through 2018. He views this scenario as "neutral to negative" for the stock. However, he recommends buying the shares on any weakness, citing what he sees as upcoming positive catalysts, including opportunities in bladder, breast and lung, new data, "and potential revenue beats from broadening use and 1H18 label expansion." He keeps a $33 price target and a Buy rating on the shares.
10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
10/16/17
PIPR
10/16/17
NO CHANGE
Target $33
PIPR
Overweight
Exelixis price target raised to $33 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis shares to $33 after the company said the Phase III Celestial trial of Cabometyx met the primary endpoint. The analyst is confident front-line approval next year will grow renal cell carcinoma product sales to $392M in 2018. He reiterates an Overweight rating on Exelixis.
BMY Bristol-Myers
$62.90

0.38 (0.61%)

10/30/17
10/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) upgraded to Outperform from Market Perform at BMO Capital with analyst Ambrish Srivastava saying the company is starting to execute on delivering operating leverage and also show discipline in its operating model. 2. Conagra Brands (CAG) upgraded to Buy from Hold at Stifel with analyst Christopher Growe citing the stock's valuation, the company's operating profit growth and its optionality to do "aggressive" share repurchase and M&A. 3. Praxair (PX) upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing the company's accelerating growth. 4. Bristol-Myers (BMY) upgraded to Buy from Hold at SunTrust with analyst John Boris saying Merck's (MRK) KN-189 data delay to 2019 and withdrawal of its EU 1L NSCLC filing improves the company's competitive position. 5. Curtiss-Wright (CW) upgraded to Buy from Neutral at BofA/Merrill with analyst Kristine Liwag saying it is a significant beneficiary of US Navy submarines and embedded computing. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/03/17
STFL
11/03/17
NO CHANGE
Target $25
STFL
Buy
NewLink Genetics price target lowered to $25 from $29 at Stifel
Stifel analyst Stephen Willey trimmed his price target on NewLink Genetics (NLNK) to $25 from $29 to reflect incremental dilution from its recent equity fundraising and forecast for increased operating expenses given that the company will soon initiate its pivotal Phase 3 melanoma trial. The analyst, who expects NewLink shares to remain sensitive to near-term data points on the IDO inhibitor front from Bristol-Myers (BMY) and the partnership of Incyte (INCY) and Merck (MRK), keeps a Buy rating on NewLink shares.
11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
OVID Ovid Therapeutics
$11.21

0.5 (4.67%)

05/30/17
WBLR
05/30/17
INITIATION
WBLR
Outperform
Ovid Therapeutics initiated with an Outperform at William Blair
William Blair analyst Tim Lugo started Ovid Therapeutics with an Outperform rating saying the company is an "emerging player" in rare neurologic disorders.
05/30/17
05/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ovid Therapeutics (OVID) was initiated with a Buy at Citi and an Outperform at William Blair, JMP Securities, and Cowen. 2. Antero Midstream Partners (AM) was resumed with an Overweight at Morgan Stanley, initiated with an Outperform at Credit Suisse, and reinstated with an Overweight at Barclays. 3. Antero Midstream GP (AMGP) was initiated with an Overweight at Morgan Stanley, JPMorgan, and Barclays, an Outperform at Baird and Credit Suisse, a Market Perform at Wells Fargo, a Strong Buy at Raymond James, a Buy at Goldman Sachs, Ladenburg, and DA Davidson, as well as a Hold at Stifel. 4. Biohaven Pharmaceutical (BHVN) was initiated with an Outperform at William Blair, an Overweight at Piper Jaffray and Barclays, as well as a Buy at Needham. 5. Pieris Pharmaceuticals (PIRS) initiated with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/17
SBSH
05/30/17
INITIATION
Target $21
SBSH
Buy
Ovid Therapeutics initiated with a Buy at Citi
Target $21.
05/30/17
JMPS
05/30/17
INITIATION
JMPS
Outperform
Ovid Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler started coverage of Ovid with a $26 price target and an Outperform rating. The analyst says that the company has "expertise" and a good track record. He notes that the company has developed a treatment, currently undergoing a Phase 2 trial ,for Angelman Syndrome, for which there are no approved treatments and no other drug in development. Butler adds that Ovid is developing a treatment for rare epileptic encephalopathies in conjunction with Takeda.
BLUE bluebird bio
$167.30

0.85 (0.51%)

11/06/17
EVER
11/06/17
DOWNGRADE
EVER
In Line
bluebird bio downgraded to In Line from Outperform at Evercore ISI
11/03/17
MSCO
11/03/17
UPGRADE
MSCO
Equal Weight
bluebird bio upgraded to Equal Weight from Underweight at Morgan Stanley
11/03/17
11/03/17
UPGRADE
Target $151

Equal Weight
bluebird bio upgraded to Equal Weight after sickle cell data at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison upgraded bluebird bio to Equal Weight from Underweight after the updated data released with ASH abstracts indicated advancement translating engrafted cells to peripheral VCN, which could yield significant hemoglobin production. He raised his price target on bluebird bio shares to $151 from $105 given the better sickle cell data, but still sees the valuation of the shares as "full."
11/06/17
RHCO
11/06/17
NO CHANGE
Target $163
RHCO
Buy
bluebird bio price target raised to $163 from $108 at SunTrust
SunTrust analyst Edward Nash raised his price target on bluebird bio to $163 and kept his Buy rating after the company's updates on the Northstar study for transfusion-dependent beta-thalassemia and the HGB-206 study for sickle cell disease. Nash says he is very pleased with bluebird's continued clinical success, noting that his price target now reflects increased probabilities of success in those programs as well as the addition of anti-BCMA CAR T program into his model.
DOVA Dova Pharmaceuticals
$28.27

0.44 (1.58%)

08/31/17
RAJA
08/31/17
NO CHANGE
RAJA
Market Perform
Investors wrong to think Fosun will acquire Impax, says Raymond James
Raymond James analyst Elliot Wilbur says shares of Impax Laboratories (IPXL) are up 20% after Shanghai Fosun Pharmaceutical disclosed this morning a 5.19% stake in the company. Investors interpreting the investment as strategic, setting up an eventual takeover of Impax, is inaccurate, Wilbur tells investors in a research note. The analyst points out that Shanghai Fosun has a New York-based investment arm with positions in companies including Valeant Pharmaceuticals (VRX), Dova Pharmaceuticals (DOVA) and Nature's Sunshine Products (NATR). The stake is just a passive investment made because the investment arm of Shanghai Fosun believes in the Impax turnaround story "and nothing more," Wilbur contends. He keeps a Market Perform rating on Impax. The stock in afternoon trading is up 20%, or $3.62, to $21.58.
11/28/17
JEFF
11/28/17
NO CHANGE
Target $33
JEFF
Buy
Dova Pharmaceuticals price target raised to $33 from $30 at Jefferies
Jefferies analyst Eun Yang raised her price target for Dova Pharmaceuticals to $33 after avatrombopag received FDA priority review with an action date of May 21, 2018. The analyst sees a higher probability for regulatory success of 95% and potential approval three months earlier than previously thought. She keeps a Buy rating on Dova.
09/26/17
LEER
09/26/17
UPGRADE
LEER
Outperform
Dova Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
09/26/17
09/26/17
UPGRADE
Target $32

Outperform
Dova Pharmaceuticals upgraded to Outperform at Leerink
As previously reported, Leerink analyst Geoffrey Porges upgraded Dova Pharmaceuticals to Outperform from Market Perform after Shionogi announced results from its phase III trial investigating thrombopoietin receptor agonist lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure. The analyst notes that lusutrombopag is from the same class of drugs as Dova's avatrombopag, but is less effective ex-Japan, and believes Dova's avatrombopag has advantage. Porges also raised his price target on Dova's shares to $32 from $24.
LLY Eli Lilly
$84.96

-0.09 (-0.11%)

11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/21/17
PIPR
11/21/17
NO CHANGE
PIPR
Piper says selection for Lilly 'diabetes ecosystem' a clear positive for Dexcom
Piper Jaffray analyst Matt O'Brien said it was news to him that Eli Lilly (LLY) is developing a diabetes pump and smart pen as part of its "diabetes ecosystem" plans. The company's selection of Dexcom's (DXCM) CGM as part of their integrated system is a clear positive for Dexcom, while Lilly's launch of an integrated system in the U.S. market is a modest negative for Insulet (PODD) and Tandem Diabetes (TNDM) given it will create a competitive headwind starting in 2021, added O'Brien.
10/24/17
PIPR
10/24/17
NO CHANGE
Target $107
PIPR
Overweight
Eli Lilly Humalog fears overblown, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss attributes Eli Lilly's (LLY) post-earnings decline to further anxiety around price competition in the U.S. diabetes segment after the company said on its earnings call that it will not challenge Sanofi's (SNY) biosimilar for Humalog. However, he sees these concerns as substantially overdone, pointing to the 39% year-over-year growth reported in Q3 for the diabetes franchise, and view today's pullback as a clear buying opportunity. Purkiss keeps an Overweight rating on Eli Lilly and raised his price target on the stock to $107 from $105.
DVAX Dynavax
$19.50

-0.05 (-0.26%)

11/15/17
BMOC
11/15/17
INITIATION
Target $11
BMOC
Outperform
VBI Vaccines initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim started VBI Vaccines (VBI) with an Outperform rating and $11 price target. The analyst believes the company's Phase III hepatitis B virus vaccine, Sci-B-Vac, will be preferred over Dynavax's (DVAX) Heplisav-B in the premium-priced HBV vaccine market.
09/12/17
EAMC
09/12/17
NO CHANGE
EAMC
Dynavax weakness a buying opportunity, says Empire
10/16/17
RBCM
10/16/17
NO CHANGE
RBCM
Dynavax selloff from updated ACIP agenda 'unfounded,' says RBC Capital
RBC Capital said the selloff in Dynavax shares from the updated ACIP agenda unfounded DVAX is trading down on unwarranted concerns around an updated ACIP agenda excluding a Heplisav vote. The firm's analyst said the new agenda without the vote for Heplisav is in-line with committee practice and as the ACIP is not allowed to vote on a recommendation until a vaccine has been approved and there is a label to vote on.
09/15/17
CANT
09/15/17
INITIATION
Target $24
CANT
Overweight
Dynavax initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Elemer Piros started Dynavax Technologies with an Overweight rating and $24 price target. The company is poised for an approval of its novel hepatitis B vaccine candidate for the prevention of HBV in adult patients, the analyst wrote last night in a research note. He assigns a 95% probability of success for Heplisav-B, which has an FDA action date of November 9.
GWPH GW Pharmaceuticals
$120.57

-3.5 (-2.82%)

10/03/17
MZHO
10/03/17
NO CHANGE
Target $51
MZHO
Buy
Zogenix price target raised to $51 from $28 at Mizuho
Mizuho analyst Difei Yang raised his price target for Zogenix (ZGNX) to $51 from $28 after it announced positive topline data for its pivotal phase III trial of ZX008 in Dravet Syndrome - Study 1. The analyst notes study 1 met its primary endpoint, with topline results indicating a clear dose response, efficacy appears better than GW Pharma's (GWPH) Epidiolex, and mechanism of action involving Sig-1R receptor could explain the higher specificity of ZX-008. Yang argues that these findings may allow ZX-008 to be positioned before Epidiolex as a treatment option for Dravet Syndrome patients. He reiterates a Buy rating on Zogenix's shares.
11/21/17
CANT
11/21/17
NO CHANGE
Target $208
CANT
Overweight
Abstracts put GW's drug-drug interaction issue to rest, says Cantor
Cantor Fitzgerald analyst Elemer Piros says the American Epilepsy Society published last night 20 abstracts detailing the safety/efficacy of GW Pharmaceuticals' Epidiolex in a multitude of controlled trials and refractory epilepsy indications. GW and collaborators "finally laid the somewhat common concern to rest: does the drug work partly or solely due to a boosting effect on another anti-epileptic drug commonly used, Clobazam?" Piros tells investors in a research note. He believes the answer is "partly." The bear thesis of Epidiolex working "solely" through boosting Clobazam's efficacy has been qualitatively debunked by management before, and now there are numbers to back it up, the analyst adds. He expects a potential approval for Epidiolex in April 2018. Piros has an Overweight rating on GW Pharmaceuticals with a $208 price target. The stock in premarket trading is up $5.23 to $120.00.
09/29/17
WBLR
09/29/17
UPGRADE
WBLR
Outperform
William Blair calls Zogenix data best to date in upgrade to Outperform
William Blair analyst Tim Lugo earlier today upgraded Zogenix (ZGNX) to Outperform from Market Perform saying the company's Dravet data is the best to date. Zogenix's ZX008 looks superior to GW Pharmaceuticals' (GWPH) cannabinoid candidate, Epidiolex, Lugo told investors in a research note. Shares of Zogenix are up 179% to $35.88 after the company this morning announced positive top-line results from its first Phase 3 trial for ZX008 for the treatment of Dravet syndrome. GW Pharmaceuticals is down 8% to $102.79 in afternoon trading.
11/20/17
STFL
11/20/17
NO CHANGE
Target $55
STFL
Buy
Physicians expressed excitement for Zogenix epilepsy treatment, says Stifel
After hosting a panel to discuss new developments for rare epileptic conditions, Stifel analyst Annabel Samimy noted that physicians in the space said they believed there was a place for both Zogenix's (ZGNX) fenfluramine and GW Pharmaceuticals' (GWPH) Epidiolex, the two most advanced treatments for Dravet Syndrome and Lennox-Gastaut Syndrome. Excitement for their introductions was "palpable, particularly for fenfluramine," added Samimy, who has a Buy rating and $55 price target on Zogenix and does not cover GW Pharmaceuticals.
BIIB Biogen
$319.96

2.82 (0.89%)

11/28/17
BERN
11/28/17
NO CHANGE
Target $318
BERN
Outperform
Biogen price target raised to $318 from $310 at Bernstein
Bernstein analyst Aaron Gal raised his price target for Biogen (BIIB) to $318 from $310 after the company announced a licensing agreement with Alkermes (ALKS) to develop and commercialize ALKS 8700, a modified fumarate with a potentially differentiated GI tolerability profile. The analyst views this important improvement in Biogen's position in MS given the risk of generic Tecfidera. Further, Gal thinks the Street may be underappreciating the value of the asset. He reiterates an Outperform rating on Biogen's shares.
11/28/17
FBCO
11/28/17
NO CHANGE
Target $66
FBCO
Outperform
Alkermes agreement with Biogen should help monetize ALKS 8700, says Credit Suisse
Credit Suisse analyst Vamil Divan views Alkermes (ALKS) ALKS 8700 agreement with Biogen (BIIB) as a positive financial move for an underappreciated pipeline asset. The analyst notes that ALKS 8700 has not been given much credit by investors to date due to limited clinical data and patent uncertainty. Divan reiterates an Outperform rating and $66 price target on Alkermes shares.
11/27/17
JEFF
11/27/17
NO CHANGE
Target $66
JEFF
Buy
Alkermes made prudent move selling ALKS 8700 rights, says Jefferies
Jefferies analyst Biren Amin thinks Alkermes (ALKS) made a prudent move by selling the rights of ALKS 8700 to Biogen (BIIB). The multiple sclerosis drug did not fit into the company's portfolio, Amin tells investors in an intraday research note. He believes Alkermes can now focus on programs such as ALKS-4230, an IL-2 for oncology. The analyst has a Buy rating on the shares with a $66 price target.
11/27/17
PIPR
11/27/17
NO CHANGE
PIPR
Overweight
Piper says Biogen strengthens MS franchise with 'reasonable' Alkermes deal
Piper Jaffray analyst Christopher Raymond said he sees the terms of Biogen's (BIIB) license and collaboration agreement to develop and commercialize Alkermes' (ALKS) ALKS 8700 as "reasonable" and he thinks the decision to in-license the drug makes sense and strengthens the Tecfidera franchise. Raymond maintains an Overweight rating on Biogen shares.
AMGN Amgen
$172.23

1.97 (1.16%)

11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold from Buy at Argus
11/29/17
PIPR
11/29/17
NO CHANGE
Target $190
PIPR
Overweight
Piper still bullish on Amgen after management meeting
Piper Jaffray analyst Christopher Raymond says he remains bullish on Amgen shares after hosting the company's management at his firm's healthcare conference. The analyst sees near-term pipeline catalysts from Amgen's immuno-oncology approach, which he sees coming more into focus, Repatha label expansion, Parsabiv launch and Aimovig approval/launch next year. Raymond maintains an Overweight rating on the shares with a $190 price target.
10/31/17
PIPR
10/31/17
NO CHANGE
Target $170
PIPR
Overweight
Piper says Amgen more credible biosimilar threat to Alexion in Europe
Piper Jaffray analyst Christopher Raymond believes Amgen's (AMGN) threat of a biosimilar alternative to Alexion Pharmaceuticals' (ALXN) Soliris may be more credible and near-term than he previously thought. The analyst highlights a Phase 3 study recently listed in the European Union's Clinical Trials Registry, which was authorized in August, as well as evidence of Amgen's active opposition to Alexion's intellectual property extension efforts in Europe. He reminds investors that two-thirds of Soliris' revenue is outside the U.S. Given this new evidence, "it would appear the real battleground may be Europe," Raymond tells investors in a research note. He keeps an Overweight rating on Alexion with a $170 price target. He views the company as well positioned to defend itself against Amgen.
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold at Argus on secular slowdown in sales of top drugs
As reported earlier, Argus analyst David Toung downgraded Amgen to Hold from Buy, noting a "secular" slowdown in sales of the company's top three products - Enbrel, Neulasta and Aranesp. Toung says the sales of growth prospects Prolia, Kyprolis and Repatha are not yet large enough to offset the declines in the three established drugs which face generic competition after losing patent protection. The analyst notes that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal challenges.
CRSP Crispr Therapeutics
$18.66

-0.55 (-2.86%)

07/13/17
RHCO
07/13/17
INITIATION
Target $16
RHCO
Hold
CRISPR Therapeutics initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Crispr Therapeutics assumed with an Overweight at Barclays
Barclays assumed Crispr with an Overweight rating and a $29 price target, up from $22, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
ONCE Spark Therapeutics
$73.27

0.34 (0.47%)

10/13/17
CANT
10/13/17
NO CHANGE
Target $105
CANT
Overweight
Spark Therapeutics price target raised to $105 from $94 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Spark Therapeutics to $105 following the unanimous advisory committee recommendation to approve Luxturna for the treatment of biallelic RPE65 mutation-associated retinal dystrophy. The analyst expects expedited approval for Luxturna well before its January 12, 2018, FDA action date. He keeps an Overweight rating on Spark Therapeutics.
10/16/17
HCWC
10/16/17
NO CHANGE
Target $30
HCWC
Buy
Abeona Therapeutics price target raised to $30 from $20 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Abeona Therapeutics (ABEO) to $30 saying the company's R&D day showcased its pipeline value. Further, the FDA panel vote for Spark Therapeutics' (ONCE) Luxturna indicates a positive gene therapy outlook, the analyst tells investors in a research note. He reiterates a Buy rating on Abeona.
10/13/17
STFL
10/13/17
NO CHANGE
Target $101
STFL
Buy
Spark Therapeutics price target raised to $101 from $92 at Stifel
Stifel analyst Stephen Willey said the vote of an FDA advisory committee in favor of the overall benefit-risk profile of Spark Therapeutics' voretigene neparvovec was "precisely in-line" with both his and the consensus expectation and he now expects the pricing/reimbursement debate to accelerate ahead of the January PDUFA date for the treatment. The analyst, who has adjusted both his expectations for pricing and some patient-related factors, raised his price target on Spark shares to $101 from $92 and keeps a Buy rating on the stock.
10/16/17
RHCO
10/16/17
NO CHANGE
Target $101
RHCO
Buy
Spark Therapeutics price target raised to $101 from $95 at SunTrust
SunTrust analyst Edward Nash raised his price target on Spark Therapeutics to $101, citing the latest FDA AdCom support for Luxturna. The analyst says the positive recommendation and the liberal stance taken by the AdCom on labeling increases Luxturna probability of success, maintaining a Buy rating on Spark Therapeutics stock.
ALNY Alnylam
$128.14

-1.6 (-1.23%)

11/03/17
COWN
11/03/17
NO CHANGE
Target $151
COWN
Outperform
Alnylam price target raised to $151 from $117 at Cowen
Cowen analyst Ritu Baral raised her price target on Alnylam to $151 from $117 following its presentation of full data from the Phase 3 APOLLO trial of patisiran. The data showed benefits in cardiac measure and excellent safety and approval should be expected in 2018 with a broad label. Baral reiterated her Outperform rating on Alnylam shares.
11/09/17
JPMS
11/09/17
UPGRADE
Target $162
JPMS
Overweight
Alnylam upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Alnylam Pharmaceuticals saying he believes patisiran "has definitively solidified" a dominant market position in the ATTR amyloidosis space. The analyst expects a "smooth regulatory process" for patisiran and broad label enabling use in the mutant mixed FAC phenotype. Rama raised his price target for Alnylam shares to $162 from $86.
11/17/17
PIPR
11/17/17
NO CHANGE
Target $182
PIPR
Overweight
Piper trims Alnylam target to $182 after capital raise
Piper Jaffray analyst Edward Tenthoff trimmed his price target for Alnylam Pharmaceuticals to $182 from $188 to account for dilution from the company's issuance of 6.44M shares at $125. The company's cash position of $1.93B will allow for the patisiran launch and pipeline advancements, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Alnylam.
11/08/17
LEHM
11/08/17
NO CHANGE
Target $158
LEHM
Overweight
Alnylam price target raised to $158 from $127 at Barclays
Barclays analyst Gena Wang raised her price target for Alnylam Pharmaceuticals to $158 saying the company highlighted multiple pipeline progresses during the Q3 earnings call. The analyst keeps an Overweight rating on the shares.
DERM Dermira
$24.05

0.71 (3.04%)

11/07/17
LEER
11/07/17
NO CHANGE
Target $41
LEER
Outperform
Dermira price target lowered to $41 from $47 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Dermira to $41 from $47 after the company unexpectedly announced the termination of its Cimzia agreement with UCB in concert with its Q3 financial update. The analyst reiterates an Outperform rating on the shares.
09/08/17
CANT
09/08/17
NO CHANGE
Target $45
CANT
Overweight
Things keep getting better for Dermira, says Cantor
In a research note titled "Things Just Keep Getting Better Ahead of Stock Moving Catalysts In 2018," Cantor Fitzgerald analyst Louise Chen says she sees three things that may be driving Dermira (DERM) shares higher. New data which support and improve the commercial opportunity for Cimzia and DRM04, positive Phase 2b data from AbbVie's (ABBV) atopic dermatitis drug, which could help expand the market and the opportunity for Dermira's Lebrikizumab, and positive meetings with investors at a healthcare conference yesterday, Chen tells investors. The analyst keeps an Overweight rating on the shares with a $45 price target.
06/30/17
06/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with an Underperform at Evercore ISI. 2. Hill-Rom (HRC) initiated with a Buy at Needham and Neutral at Cantor. 3. Dermira (DERM) initiated with an Outperform at Evercore ISI. 4. Coach (COH) initiated with a Buy at Canaccord. 5. WWE (WWE) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/17
LEER
10/12/17
NO CHANGE
Target $47
LEER
Outperform
Mid/late-stage pipeline to transform Dermira into 'major player,' says Leerink
Leerink analyst Seamus Fernandez sees Dermira's mid- and late-stage pipeline transforming the company into a "major player" in dermatology starting in 2018. With the completion of enrollment in the CLAREOS-1 and CLAREOS-2 studies, the analyst believes Dermira represents a "unique investment opportunity" for investors, with approvals for Cimzia and DRM04 likely in 2018, in addition to the Phase 3 readouts of a uniquely value-added acne therapy in DRM01 in Q1 of 2018. Assuming positive top-line results, Fernandez sees upside of $12-$17 less the likely dilution of $5-$7 from convertible debt on data readout, which assumes clear efficacy and a safety profile similar to what was observed in Phase 2 studies. He reiterates an Outperform rating and $47 price target on the shares.
TOCA Tocagen
$11.79

0.48 (4.24%)

05/08/17
STFL
05/08/17
INITIATION
STFL
Buy
Tocagen initiated at Stifel
As noted earlier, Stifel started coverage of Toca with a $24 price target and a Buy rating. Analyst Thomas Shrader says that data on the company's combination cancer treatment, TOCA-511 + TOCA-FC, in high grade glioma is "intriguing." "Most treated patients live longer than historical expectations and about 25% of patients experience profound responses lasting years and possibly representing a cure," he wrote. The analyst adds that "solid" data indicates that other types of solid tumors could be mitigated using the drug combination.
05/08/17
LEER
05/08/17
INITIATION
Target $19
LEER
Market Perform
Tocagen initiated with a Market Perform at Leerink
Leerink analyst Michael Schmidt started Tocagen with a Market Perform rating and $19 price target.
05/08/17
05/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yext (YEXT) initiated with an Outperform at RBC Capital, with an Overweight at Piper Jaffray, with an Equal Weight at Morgan Stanley and with a Neutral at JPMorgan. 2. Netshoes (NETS) initiated with an Overweight at JPMorgan and with a Buy at Jefferies. 3. Tocagen (TOCA) initiated with a Buy at Stifel and with a Market Perform at Leerink. 4. Warrior Met Coal (HCC) initiated with an Outperform at BMO Capital, with an Overweight at Morgan Stanley, with an Outperform at Credit Suisse and with a Neutral at Citi. 5. Cadence Bancorporation (CADE) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/17
EVER
05/09/17
INITIATION
Target $28
EVER
Outperform
Tocagen initiated with an Outperform at Evercore ISI
Evercore ISI analyst Jonathan Miller initiated Tocagen with an Outperform and a $28 price target
JAZZ Jazz Pharmaceuticals
$137.87

-1.74 (-1.25%)

11/10/17
11/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Holly Energy (HEP) reinstated with an Equal Weight at Barclays. 2. Jazz Pharmaceuticals (JAZZ) assumed with a Neutral at H.C. Wainwright. 3. TE Connectivity (TEL) initiated with an Outperform at Wells Fargo. 4. Opus Bank (OPB) initiated with an Outperform at Fig Partners. 5. Amphenol (APH) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/17
HCWC
11/10/17
INITIATION
Target $150
HCWC
Neutral
Jazz Pharmaceuticals assumed with a Neutral at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat assumed coverage of Jazz Pharmaceuticals with a Neutral rating and $150 price target. The analyst believes visibility for Xyrem growth is "hazy."
11/13/17
JPMS
11/13/17
NO CHANGE
Target $185
JPMS
Overweight
JPMorgan still sees 'compelling opportunity' in Jazz shares
After hosting a call with management CEO Bruce Cozadd, JPMorgan analyst Jessica Fye sees 2018 as a year of reaccelerating Xyrem growth and a strong Vyxeos launch for Jazz Pharmaceuticals. With the shares trading at 11 times her 2018 earnings estimate, Fye continues to see Jazz as a "compelling opportunity." The company poised to generate double-digit earnings growth over the next several years, the analyst tells investors in a research note.
11/08/17
JANY
11/08/17
NO CHANGE
Target $186
JANY
Buy
Janney would be a buyer of Jazz Pharmaceuticals on post-earnings weakness
Janney Capital analyst Ken Trbovich recommends being a buyer of Jazz Pharmaceuticals shares following the company's "mixed" Q3 report, as he continues to see Jazz being excellently positioned for long-term sustainable growth given the recent launch of Vyxeos, the expected approval and launch of JZP-110 and line extensions for Xyrem. Based on reduced estimates, he lowered his fair value estimate on Jazz shares to $186 from $192, but he maintains a Buy rating on the stock.
RGNX Regenxbio
$26.80

-1.45 (-5.13%)

11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
MSCO
11/09/17
INITIATION
Target $34
MSCO
Overweight
Regenxbio resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Regenxbio with an Overweight rating and a $34 price target, saying he expects updates from its Phase 1 studies of RGX-501 and RGX-314 in early January to be the next catalysts for the stock.
11/22/17
LEHM
11/22/17
INITIATION
Target $38
LEHM
Overweight
Regenxbio initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Regenxbio with an Overweight rating and $38 price target. The analyst views the company's patent portfolio as "strong" and sees "significant upside" from its wholly owned RGX-314 program in wet age-related macular degeneration.
11/22/17
11/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Nutanix (NTNX) initiated with a Buy at Needham. 2. Regenxbio (RGNX) and Sangamo (SGMO) were initiated with an Overweight at Barclays. 3. Amedisys (AMED), HealthSouth (HLS), LHC Group (LHCG), and LifePoint (LPNT) were initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

23:00
12/13/17
12/13
23:00
12/13/17
23:00
General news
PBoC nudged rates higher »

PBoC nudged rates higher,…

LPSN

LivePerson

$11.05

-0.05 (-0.45%)

20:28
12/13/17
12/13
20:28
12/13/17
20:28
Initiation
LivePerson initiated at B. Riley FBR »

LivePerson initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HUSKF

Husky Energy

$12.42

-0.1177 (-0.94%)

20:26
12/13/17
12/13
20:26
12/13/17
20:26
Upgrade
Husky Energy rating change at Goldman Sachs »

Husky Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$51.68

-0.28 (-0.54%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Upgrade
ConocoPhillips rating change at Goldman Sachs »

ConocoPhillips upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

SAFM

Sanderson Farms

$167.64

0.64 (0.38%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DB

Deutsche Bank

$19.33

-0.05 (-0.26%)

19:17
12/13/17
12/13
19:17
12/13/17
19:17
Hot Stocks
DBNY, DBTCA raise prime lending rate to 4.5% from 4.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.04

-0.06 (-0.16%)

18:47
12/13/17
12/13
18:47
12/13/17
18:47
Hot Stocks
AT&T and Communications Workers of America reach tentative agreement »

AT&T Mobility has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$63.47

0.19 (0.30%)

18:33
12/13/17
12/13
18:33
12/13/17
18:33
Hot Stocks
Bristol-Myers granted exclusive license by Ono Pharma to develop ONO-4578 »

Bristol-Myers and Ono…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 05

    Mar

WFC

Wells Fargo

$59.40

-0.93 (-1.54%)

18:15
12/13/17
12/13
18:15
12/13/17
18:15
Hot Stocks
Breaking Hot Stocks news story on Wells Fargo »

Wells Fargo raises prime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

HBAN

Huntington Bancshares

$14.58

-0.23 (-1.55%)

18:10
12/13/17
12/13
18:10
12/13/17
18:10
Hot Stocks
Huntington Bancshares raises prime rate to 4.5% from 4.25% »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.10

-0.2 (-0.79%)

18:06
12/13/17
12/13
18:06
12/13/17
18:06
Hot Stocks
Breaking Hot Stocks news story on Associated Banc-Corp »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

$17.90

0.035 (0.20%)

18:05
12/13/17
12/13
18:05
12/13/17
18:05
Periodicals
UBS Wealth Management president Zeltner close to stepping down, Bloomberg says »

UBS Wealth Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.64

0.06 (0.16%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
Pfizer announces FDA approves IXIFI, a biosimilar to Remicade »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

CNP

CenterPoint Energy

$28.40

0.02 (0.07%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
CenterPoint Energy raises quarterly dividend 4% to 27.75c per share »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$11.99

-0.26 (-2.12%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Recommendations
MiMedx analyst commentary at Piper Jaffray »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CE

Celanese

$108.31

1.34 (1.25%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Celanese raises acetyl intermediates products prices »

Raises price on Vinyl…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$57.30

-1.25 (-2.13%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Western Alliance: Sarver to transition from chairman, CEO to exec chairman in Q1 »

Western Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.60

-0.9 (-1.62%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
U.S. Bancorp raises prime lending rate to 4.50% from 4.25%, effective Dec 14 »

U.S. Bancorp last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

WBS

Webster Financial

$56.16

-0.73 (-1.28%)

18:00
12/13/17
12/13
18:00
12/13/17
18:00
Hot Stocks
Webster raises prime lending rate to 4.5% from 4.25% »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HSBC

HSBC

$51.44

0.89 (1.76%)

17:56
12/13/17
12/13
17:56
12/13/17
17:56
Hot Stocks
Breaking Hot Stocks news story on HSBC »

HSBC raises prime,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$37.59

0.32 (0.86%)

17:47
12/13/17
12/13
17:47
12/13/17
17:47
Hot Stocks
Aqua America names CEO Christopher Franklin as board chairman »

Aqua America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MSFT

Microsoft

$85.35

-0.23 (-0.27%)

17:38
12/13/17
12/13
17:38
12/13/17
17:38
Hot Stocks
Microsoft launches new AI-powered search features for Bing »

Microsoft announced in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TCF

TCF Financial

$20.24

-0.16 (-0.78%)

17:36
12/13/17
12/13
17:36
12/13/17
17:36
Hot Stocks
Breaking Hot Stocks news story on TCF Financial »

TCF Financial raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$84.81

-1.06 (-1.23%)

17:34
12/13/17
12/13
17:34
12/13/17
17:34
Hot Stocks
Comerica Bank raises prime rate to 4.5% from 4.25% »

Comerica Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

CMCM

Cheetah Mobile

$11.18

-0.02 (-0.18%)

17:33
12/13/17
12/13
17:33
12/13/17
17:33
Hot Stocks
Breaking Hot Stocks news story on Cheetah Mobile »

Cheetah Mobile up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.